• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by 4D pharma plc

    7/19/22 11:48:36 AM ET
    $LBPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LBPS alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-250986
    Issuer: 4D Pharma PLC
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 5th Floor, 9 Bond Court
    Leeds UNITED KINGDOM LS1 2JZ
    Telephone number: 44-113-895-0130
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    American depositary shares and warrant
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2022-07-19 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LBPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LBPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $LBPS
    SEC Filings

    See more
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      1/3/23 12:09:22 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      11/18/22 2:58:44 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by 4D pharma plc

      6-K - 4D Pharma PLC (0001830162) (Filer)

      11/15/22 1:53:49 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Financials

    Live finance-specific insights

    See more
    • 4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell Carcinoma

      - Primary Efficacy Endpoint Met Early in Renal Cell Carcinoma Group in Part B of Study - Company to Host Conference Call and Webcast Today March 23, 10:00 am EST (2:00 pm GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint ahead of enrollment complet

      3/23/22 7:00:00 AM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of Asthma

      - Part A of the trial achieved the primary endpoint of safety and tolerability - Multiple secondary endpoints show positive trends in improving asthma control, supporting progression into Part B of the Phase I/II trial - Company to host conference call and webcast to discuss results today at 08:00 a.m. ET (1:00 p.m. GMT) 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces additional clinical data from Part A of its Phase I/II trial of MRx-4DP0004, an orally-delivered single strain Live Biotherapeutic being developed for the treatment of asthma.

      1/27/22 7:00:00 AM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 4D pharma plc ("4D pharma") Receives Notice of Delisting From Nasdaq

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that on June 27, 2022, it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") stating that in accordance with Listing Rules 5101, 5110(b), and IM-5101-1, Nasdaq Staff (the "Staff") has determined that 4D pharma's securities will be delisted from The Nasdaq Stock Market. Accordingly, trading of 4D pharma's LBPS will be suspended at the opening of business on July 7, 2022, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove 4D pharma's secur

      6/28/22 1:50:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Update on Suspension of Trading

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, provides an update to the announcement released earlier today regarding the Company's request for an immediate suspension of trading in the Company's ordinary shares on AIM which took effect from 12.30 p.m. (London). On 29 July 2021, the Company announced that it had agreed a senior secured credit facility (the "Facility") for up to US$30m with Oxford Finance LLC ("Oxford"), with an initial tranche of US$12.5 million drawn at closing and further tranches available dependent on the achievement of certain mileston

      6/24/22 2:41:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      - Study to assess safety of MRx0518 with BAVENCIO and effect on progression-free survival at 6 months - Study sites are open for patient enrolment 4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced the presentation of a trial in progress poster from the Phase II clinical trial of MRx0518 in combination with BAVENCIO® (avelumab), a PD-L1 blocking antibody, as a first-line maintenance therapy for patients with unresectable locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, a

      5/26/22 5:30:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by 4D pharma plc (Amendment)

      SC 13G/A - 4D Pharma PLC (0001830162) (Subject)

      3/2/22 5:24:43 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 4D pharma plc

      SC 13G - 4D Pharma PLC (0001830162) (Subject)

      2/28/22 4:17:17 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 4D pharma plc

      SC 13G - 4D Pharma PLC (0001830162) (Subject)

      2/25/22 3:52:23 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LBPS
    Leadership Updates

    Live Leadership Updates

    See more
    • 4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022

      4D pharma plc ((AIM: DDDD, NASDAQ:LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022. "2021 was a productive year for 4D pharma. We reported promising signals in the clinic from our lead candidates in immuno-oncology and inflammatory disease, and entered into our second clinical collaboration in oncology, further validating the potential for single strain Live Biotherapeutics to treat systemic disease and the MicroRx platform. Additionally, we completed the merger wit

      3/31/22 5:27:00 PM ET
      $LBPS
      Biotechnology: Pharmaceutical Preparations
      Health Care